BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26961235)

  • 1. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
    Pu F; Salarian M; Xue S; Qiao J; Feng J; Tan S; Patel A; Li X; Mamouni K; Hekmatyar K; Zou J; Wu D; Yang JJ
    Nanoscale; 2016 Jul; 8(25):12668-82. PubMed ID: 26961235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of Gd-Based prostate cancer targeted magnetic resonance agents using prostate specific membrane antigen.
    Yang JU; Kim S; Ahn JH; Kim MH; Kil HS; Chi DY; Lee KC; Lee YJ; Park JA
    Biochem Biophys Res Commun; 2022 Jun; 607():152-157. PubMed ID: 35367828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
    Bao K; Lee JH; Kang H; Park GK; El Fakhri G; Choi HS
    Chem Commun (Camb); 2017 Feb; 53(10):1611-1614. PubMed ID: 28085163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.
    Banerjee SR; Ngen EJ; Rotz MW; Kakkad S; Lisok A; Pracitto R; Pullambhatla M; Chen Z; Shah T; Artemov D; Meade TJ; Bhujwalla ZM; Pomper MG
    Angew Chem Int Ed Engl; 2015 Sep; 54(37):10778-82. PubMed ID: 26212031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
    Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
    Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
    Sillerud LO
    J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF
    Dash A; Blasiak B; Tomanek B; Latta P; van Veggel FCJM
    ACS Appl Mater Interfaces; 2021 Jun; 13(21):24345-24355. PubMed ID: 34024098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
    Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
    Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
    Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
    Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and preclinical evaluation of an Al
    Huang Y; Li H; Ye S; Tang G; Liang Y; Hu K
    Eur J Med Chem; 2021 Oct; 221():113502. PubMed ID: 33965863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging.
    Li D; Kirberger M; Qiao J; Gui Z; Xue S; Pu F; Jiang J; Xu Y; Tan S; Salarian M; Ibhagui O; Hekmatyar K; Yang JJ
    Invest Radiol; 2024 Feb; 59(2):170-186. PubMed ID: 38180819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
    Hara D; Tao W; Totiger TM; Pourmand A; Dogan N; Ford JC; Shi J; Pollack A
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):220-232. PubMed ID: 33964351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
    Leamon CP; Reddy JA; Bloomfield A; Dorton R; Nelson M; Vetzel M; Kleindl P; Hahn S; Wang K; Vlahov IR
    Bioconjug Chem; 2019 Jun; 30(6):1805-1813. PubMed ID: 31075200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
    Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
    J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
    Zhu Y; Sun Y; Chen Y; Liu W; Jiang J; Guan W; Zhang Z; Duan Y
    Int J Mol Sci; 2015 Apr; 16(5):9573-87. PubMed ID: 25927579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels.
    Sillerud LO
    Int J Nanomedicine; 2016; 11():357-71. PubMed ID: 26855574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ultrasound-responsive dual-modal US/T
    Yoon YI; Ha SW; Lee HJ
    J Magn Reson Imaging; 2018 Dec; 48(6):1610-1616. PubMed ID: 30475452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.